Oncology trials often report on progression-free survival or overall survival, but the authors of an analysis presented during a poster session today at the European Society of Medical Oncology (ESMO) Congress argue that such endpoints are less sensitive then short-term overall response rate.
Oncology trials often report on progression-free survival (PFS) or overall survival (OS), but the authors of an analysis presented during a poster session today at the European Society of Medical Oncology (ESMO) Congress argue that such endpoints are less sensitive then short-term overall response rate (ORR) in confirming biosimilarity when long median PFS or OS are expected.
The authors presented considerations on interpreting survival data as illustrated by a sensitivity analysis from a recent study of biosimilar rituximab. In a confirmatory phase 3 study, treatment-naïve patients with follicular lymphoma received either European Medicines Agency-approved GP2013 (n = 314) or reference rituximab (n = 315).
Patients who responded to an induction treatment with cyclophosphamide, vincristine, and prednisone chemotherapy received either GP2013 or reference rituximab as maintenance monotherapy.
The primary endpoint for equivalence was ORR at the end of induction. Secondary endpoints included PFS and OS.
As of December 2016, the median follow-up was 23.6 months for the GP2013 arm and 24.2 months for the reference rituximab arm. The study met its primary endpoints to confirm biosimilarity.
Median PFS and OS could not be estimated. Hazard rations for PFS and OS were 1.31 (90% confidence interval [CI]; range, 1.02 to 1.69) and 0.77 (90% CI; range, 0.29 to 1.22), respectively.
A Kaplan-Meier analysis showed that PFS survival curves diverged between 12 and 24 months, yet the curves ran parallel outside of that period, contrary to the proportional hazard assumption of the Cox model. Complete response (CR) rates were similar between treatments at all time points, including at 33 months.
The researchers concluded that a small sample size, a low event rate, data immaturity, and other aspects of study design can decrease a study’s sensitivity in biosimilarity assessments, as demonstrated by the fact that hazard ratios for PFS and OS had opposite directions, while CR rates remained similar across time.
PFS and OS results, the authors say, should be interpreted with caution, as they may not reflect either a difference or a lack of a difference between treatments.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.